A case series of refractory cutaneous sarcoidosis successfully treated with infliximab

Dermatology and Therapy

Volumn 2, Issue 1, 2012, Pages 1-9

  Tuchinda, Papapit ^b   Bremmer, Matthew ^a   Gaspari, Anthony A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Biologic; Cutaneous; Infliximab; Sarcoidosis; Therapy; Treatment; Tumor necrosis factor inhibitor

Indexed keywords

HYDROXYCHLOROQUINE; IMIQUIMOD; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THALIDOMIDE;

ADULT; AFRICAN AMERICAN; ALLOPATHY; ARTICLE; CASE REPORT; CASE STUDY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LUNG SARCOIDOSIS; MALE; MEDICAL HISTORY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REFRACTORY PERIOD; SARCOIDOSIS; SKIN BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84871160440     PISSN: None     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-012-0011-9     Document Type: Article

References (45)

1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224-34.
2. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 2005;53:917.
3. Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012;83:218-24.
4. Sene T, Juillard C, Rybojad M. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. J Am Acad Dermatol. 2012;66:328-32.
5. Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135:468-76.
6. Baughman RP, Drent M, Kavuru M, et al. Sarcoidosis Investigators: infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795-802.
7. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127: 1064-71.
8. Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L. BIOBADASER study group. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologic BIOBADASER and a systematic review. Semin Arthritis Rheum. 2012. [Epub ahead of print].
9. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135: 27-31.
10. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest. 2003;124:2028-31.
11. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 2005;53:788-91.
12. Judson MA, Baughman RP, Costabel U, et al. Centocor T48 sarcoidosis investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31: 1189-96.
13. Ahmed MM, Mubashir E, Dossabhoy NR. Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab. Clin Rheumatol. 2007;26:1346-9.
14. Garg S, Garg K, Altaf M, Magaldi JA. Refractory vertebral sarcoidosis responding to infliximab. J Clin Rheumatol. 2008;14:238-40.
15. Migliore A, Signore A, Capuano A, et al. Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report. Eur Rev Med Pharmacol Sci. 2008;12: 127-30.
16. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol. 2006;41:766-8.
17. Kahler CM, Heininger P, Loeffler-Ragg J, Vogelsinger H. Infliximab therapy in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2007; 176:417. Author reply 417-18.
18. Cruz BA, Reis DD, Araujo CA. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int. 2007;27: 1181-3.
19. Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with infliximab. J Neurol Neurosurg Psychiatry. 2010;81:241-6.
20. Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol. 2007;26:2001-3.
21. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100:2053-9.
22. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005;141:910-1.
23. Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14:522-8.
24. Judson MA. Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance. Chest. 2009;135:1358-9.
25. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:76-89.
26. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72:337-40.
27. Rosen T, Doherty C. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion. Dermatol Online J. 2007;13:14.
28. Moller DR. Treatment of sarcoidosis-from a basic science point of view. J Intern Med. 2003;253: 31-40.
29. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153-65.
30. Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol. 2007;25:276-87.
31. Marchell RM, Judson MA. Chronic cutaneous lesions of sarcoidosis. Clin Dermatol. 2007;25: 295-302.
32. Marcoval J, Mana J, Moreno A, Peyri J. Subcutaneous sarcoidosis-clinicopathological study of 10 cases. Br J Dermatol. 2005;153:790-4.
33. Manonukul J, Wanitphakdeedecha R, Wisuthsarewong W, Thirapote P. Histopathologic aid to diagnosis of sarcoidosis: report of 8 cases. J Med Assoc Thai. 2006;89:864-71.
34. Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol. 2007;56:69-83.
35. Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J. 2003;21:421-8.
36. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha: new drugs used to modulate inflammatory diseases. Dermatol Clin. 2001;19: 617-35.
37. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J. Sarcoidosis: TNFalpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997;156:1586-92.
38. Zheng L, Teschler H, Guzman J, Hubner K, Striz I, Costabel U. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med. 1995;152:1061-6.
39. Prasse A, Georges CG, Biller H, et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4? and CD8? T cells. Clin Exp Immunol. 2000;122:241-8.
40. Zissel G, Muller-Quernheim J. Sarcoidosis: historical perspective and immunopathogenesis (Part I). Respir Med. 1998;92:126-39.
41. Nozaki K, Silver RM, Stickler DE, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011;342: 352-5.
42. Daien CI, Monnier A, Claudepierre P, et al. Club Rhumatismes et Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48:883-6.
43. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006;55:978-81.
44. Izzi S, Francesconi F, Visca P, et al. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. Dermatol Online J. 2010;16:16.
45. Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology. 2010; 220:234-7.